| Jonathan D Vacik, MD | |
|
200 Groton Rd, Ayer, MA 01432-1168 | |
| (978) 784-9000 | |
| Not Available |
| Full Name | Jonathan D Vacik |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 23 Years |
| Location | 200 Groton Rd, Ayer, Massachusetts |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1528129640 | NPI | - | NPPES |
| 110039191A | Medicaid | MA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207PE0004X | Emergency Medicine - Emergency Medical Services | 12824 (New Hampshire) | Secondary |
| 207P00000X | Emergency Medicine | 220308 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Healthalliance Hospitals, Inc | Leominster, MA | Hospital |
| Northeastern Vermont Regional Hospital | Saint johnsbury, VT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Umass Memorial Medical Group Inc | 4284539891 | 1889 |
| Northeastern Vermont Regional Hospital Inc | 3678481405 | 102 |
News Archive
Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today reported results from two studies of VELCADE (bortezomib) for Injection based combinations in patients with relapsed or refractory multiple myeloma (MM).
Forbius, a clinical stage company developing biotherapeutics targeting EGFR and TGF-β pathways, today announced that the first patient has been dosed in a Phase 2a trial evaluating the efficacy and safety of AVID100 in patients with squamous non-small cell lung cancer whose tumors overexpress epidermal growth factor receptor.
One of the most vexing aspects of the COVID-19 pandemic is doctors' inability to predict which newly hospitalized patients will go on to develop severe disease, including complications that require the insertion of a breathing tube, kidney dialysis or other intensive care.
In September 2015, then 44 year-old CEO of BioViva USA Inc. Elizabeth Parrish received two of her own company's experimental gene therapies: one to protect against loss of muscle mass with age, another to battle stem cell depletion responsible for diverse age-related diseases and infirmities.
› Verified 6 days ago
| Entity Name | Umass Memorial Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760445373 PECOS PAC ID: 4284539891 Enrollment ID: O20040113000267 |
News Archive
Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today reported results from two studies of VELCADE (bortezomib) for Injection based combinations in patients with relapsed or refractory multiple myeloma (MM).
Forbius, a clinical stage company developing biotherapeutics targeting EGFR and TGF-β pathways, today announced that the first patient has been dosed in a Phase 2a trial evaluating the efficacy and safety of AVID100 in patients with squamous non-small cell lung cancer whose tumors overexpress epidermal growth factor receptor.
One of the most vexing aspects of the COVID-19 pandemic is doctors' inability to predict which newly hospitalized patients will go on to develop severe disease, including complications that require the insertion of a breathing tube, kidney dialysis or other intensive care.
In September 2015, then 44 year-old CEO of BioViva USA Inc. Elizabeth Parrish received two of her own company's experimental gene therapies: one to protect against loss of muscle mass with age, another to battle stem cell depletion responsible for diverse age-related diseases and infirmities.
› Verified 6 days ago
| Entity Name | Steward Emergency Physicians Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780971275 PECOS PAC ID: 0244401404 Enrollment ID: O20110919000768 |
News Archive
Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today reported results from two studies of VELCADE (bortezomib) for Injection based combinations in patients with relapsed or refractory multiple myeloma (MM).
Forbius, a clinical stage company developing biotherapeutics targeting EGFR and TGF-β pathways, today announced that the first patient has been dosed in a Phase 2a trial evaluating the efficacy and safety of AVID100 in patients with squamous non-small cell lung cancer whose tumors overexpress epidermal growth factor receptor.
One of the most vexing aspects of the COVID-19 pandemic is doctors' inability to predict which newly hospitalized patients will go on to develop severe disease, including complications that require the insertion of a breathing tube, kidney dialysis or other intensive care.
In September 2015, then 44 year-old CEO of BioViva USA Inc. Elizabeth Parrish received two of her own company's experimental gene therapies: one to protect against loss of muscle mass with age, another to battle stem cell depletion responsible for diverse age-related diseases and infirmities.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jonathan D Vacik, MD 60 High St, Andover, MA 01810-3529 Ph: () - | Jonathan D Vacik, MD 200 Groton Rd, Ayer, MA 01432-1168 Ph: (978) 784-9000 |
News Archive
Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today reported results from two studies of VELCADE (bortezomib) for Injection based combinations in patients with relapsed or refractory multiple myeloma (MM).
Forbius, a clinical stage company developing biotherapeutics targeting EGFR and TGF-β pathways, today announced that the first patient has been dosed in a Phase 2a trial evaluating the efficacy and safety of AVID100 in patients with squamous non-small cell lung cancer whose tumors overexpress epidermal growth factor receptor.
One of the most vexing aspects of the COVID-19 pandemic is doctors' inability to predict which newly hospitalized patients will go on to develop severe disease, including complications that require the insertion of a breathing tube, kidney dialysis or other intensive care.
In September 2015, then 44 year-old CEO of BioViva USA Inc. Elizabeth Parrish received two of her own company's experimental gene therapies: one to protect against loss of muscle mass with age, another to battle stem cell depletion responsible for diverse age-related diseases and infirmities.
› Verified 6 days ago
Dr. Richard Gregory Lyons, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 200 Groton Rd, Ayer, MA 01432 Phone: 978-784-9250 | |
Joseph Gregory Kline Benedict, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 200 Groton Rd, Ayer, MA 01432 Phone: 978-784-9250 | |
Dr. Steven Charles Balser, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 200 Groton Rd, Ayer, MA 01432 Phone: 978-784-9000 |